Get access
Clinical & Experimental Allergy

Atopic and non-atopic allergic disorders: current insights into the possible involvement of free immunoglobulin light chains

Authors

  • T. Groot Kormelink,

    1. Division of Pharmacology and Pathophysiology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Search for more papers by this author
    • 1T. Groot Kormelink and M. Thio have equally contributed to this manuscript.

  • M. Thio,

    1. Division of Pharmacology and Pathophysiology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Search for more papers by this author
    • 1T. Groot Kormelink and M. Thio have equally contributed to this manuscript.

  • B. R. Blokhuis,

    1. Division of Pharmacology and Pathophysiology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Search for more papers by this author
  • F. P. Nijkamp,

    1. Division of Pharmacology and Pathophysiology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Search for more papers by this author
  • F. A. Redegeld

    1. Division of Pharmacology and Pathophysiology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Search for more papers by this author

Correspondence:
Frank Redegeld, Department of Pharmaceutical Sciences, Division of Pharmacology and Pathophysiology, Faculty of Science, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands. E-mail: f.a.m.redegeld@uu.nl

Summary

Allergic diseases have become a serious global health problem in the developed world. IgE interacting with its high-affinitiy receptor FcɛRI is considered a major contributing factor to most types of allergies, but depending on the type of allergy, however, a subgroup of patients displays common symptoms and yet lack elevated levels of total serum IgE and/or antigen-specific IgE. Novel therapeutic strategies such as anti-IgE therapy may therefore not be applicable to these patients. It is clear, however, that these patients do display activation of mast cells. In several patients suffering from immunological disorders, an increase in free immunoglobulin (IG) light chain levels can be detected. Previously, we have described the capability of free light chains to elicit immediate hypersensitivity responses. In this Opinion article, we will discuss the role of IgE- and non-IgE-mediated mechanisms in allergic disorders and point out a possible role of free IG light chains in the pathogenesis of the non-atopic types of these allergies.

Get access to the full text of this article

Ancillary